Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study.

Autor:	Elsamany S; Oncology Center, King Abdullah Medical City, Makkah, Saudi Arabia.; Oncology Center, Mansoura University, Mansoura, Egypt., Elbaiomy M; Oncology Center, Mansoura University, Mansoura, Egypt., Zeeneldin A; Oncology Center, King Abdullah Medical City, Makkah, Saudi Arabia.; National Cancer Institute, Cairo University, Cairo, Egypt., Tashkandi E; Oncology Center, King Abdullah Medical City, Makkah, Saudi Arabia.; College of Medicine, Umm AlQura University, Makkah, Saudi Arabia., Hassanin F; Oncology Center, King Abdullah Medical City, Makkah, Saudi Arabia., Abdelhafeez N; Oncology Center, King Abdulaziz Medical City, Riyadh, Saudi Arabia.; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., O Al-Shamsi H; Department of Oncology, Alzahra Hospital, Dubai, United Arab Emirates.; University of Sharjah, Sharjah, United Arab Emirates., Bukhari N; Department of Medical Oncology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.; Department of Internal Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia., Elemam O; Oncology Center, King Abdullah Medical City, Makkah, Saudi Arabia.; Oncology Center, Mansoura University, Mansoura, Egypt.
Jazyk:	angličtina
Zdroj:	JMIR cancer [JMIR Cancer] 2021 Nov 15; Vol. 7 (4), pp. e27073. Date of Electronic Publication: 2021 Nov 15.
DOI:	10.2196/27073
Abstrakt:	Background: Management of patients with cancer in the current era of the COVID-19 pandemic poses a significant challenge to health care systems. Breast cancer is the most common cancer internationally. Breast cancer is a disease that involves surgery, chemotherapy, hormonal therapy, targeted therapy, radiotherapy, and, more recently, immunotherapy in its management plan. The immune system requires months to recover from these medications, and this condition is even worse in patients with metastatic breast cancer who need ongoing treatment with these drugs. Some of these drugs, such as inhibitors of cyclin-dependent kinases 4 and 6, can cause rare but life-threating lung inflammation. Patients with breast cancer who have metastatic disease to the lungs can experience deterioration of disease symptoms with COVID-19 infection. Oncologists treating patients with breast cancer are facing a difficult situation regarding treatment choice. The impact that COVID-19 has had on breast cancer care is unknown, including how to provide the best care possible without compromising patient and community safety. Objective: The aim of this study was to explore the views of oncologists regarding the management of patients with breast cancer during the COVID-19 pandemic. Methods: A web-based SurveyMonkey questionnaire was submitted to licensed oncologists involved in breast cancer management in Saudi Arabia, Egypt, and United Arab Emirates. The survey focused on characteristics of the participants, infection risk among patients with cancer, and possible treatment modifications related to different types of breast cancer. Results: The survey was completed by 82 participants. For early hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, 61 of the 82 participants (74%) supported using neoadjuvant hormonal therapy in selected patients, and 58% (48/82) preferred giving 6 over 8 cycles of adjuvant chemotherapy when indicated. Only 43% (35/82) preferred inhibitors of cyclin-dependent kinases 4 and 6 with hormonal therapy as the first-line treatment in all patients with metastatic HR-positive disease. A total of 55 of the 82 participants (67%) supported using adjuvant trastuzumab for 6 instead of 12 months in selected patients with HER2-positive breast cancer. For metastatic HER2-positive, HR-positive breast cancer, 80% of participants (66/82) supported the use of hormonal therapy with dual anti-HER2 blockade in selected patients. The preferred choice of first-line treatment in metastatic triple negative patients with BRCA mutation and programmed cell death 1 ligand 1 (PD-L1) <1% was poly(adenosine diphosphate-ribose) polymerase inhibitor according to 41% (34/82) of the participants, and atezolizumab with nab-paclitaxel was preferred for PD-L1 >1% according to 71% (58/82) of the participants. Conclusions: Several modifications in breast cancer management were supported by the survey participants. These modifications need to be discussed on a local basis, taking into account the local infrastructure and available resources. (©Shereef Elsamany, Mohamed Elbaiomy, Ahmed Zeeneldin, Emad Tashkandi, Fayza Hassanin, Nafisa Abdelhafeez, Humaid O Al-Shamsi, Nedal Bukhari, Omima Elemam. Originally published in JMIR Cancer (https://cancer.jmir.org), 15.11.2021.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu